Head and neck cancers constitute 5% of all cancers worldwide and in the Indian population, it accounts above 50% of all malignant tumours. Most of the patients present with locally or locoregionally advanced disease. As a result of their location, these tumors can cause varying degree of functional and cosmetic deformity that are often exacerbated by cancer treatment.
INTRODUCTION
Head and neck cancers constitute 5% of all cancers worldwide and in the Indian population, it accounts above 50% of all malignant tumours. Most of the patients present with locally or locoregionally advanced disease. As a result of their location, these tumors can cause varying degree of functional and cosmetic deformity that are often exacerbated by cancer treatment.
and concurrent chemotherapy regimen that have documented improvements in local control and overall survival Currently three multimodality treatment approaches are used in treatment of head and neck cancer. The first approach is surgery, followed by adjuvant concurrent chemoradiotherapy, which enables precise pathologic staging and identification of high risk features that influence the choice of adjuvant treatment. The second approach is definitive concurrent chemoradiotherapy with surgery as an optimal salvage or completion treatment. It has the advantage of improved organ preservation.
The third approach is use of induction chemotherapy followed by definitive local therapy. 2, 3 Advantages include the potential to decrease the risk of distant failure and a rapid reduction in tumour bulk in responders. A response to induction appears to predict responsiveness to chemoradiotherapy.
Induction chemotherapy has been frequently administered in advanced head and neck cancer with an overall response rate often exceeding 75%. 4, 5 Two large landmark trials the TAX323 and TAX324, had highlighted the role of induction chemotherapy in unresectable and locally advanced head and neck cancer. The use of three drug regimen in these trials led to response rates of around 68 to 70%.
The aim of this study is to evaluate the feasibility and outcome of a two drug induction regimen with combined cisplatin and paclitaxel. In general; most trials of concurrent chemoradiation have not documented reductions in the rates of distant metastases with the addition of concurrent chemotherapy to radiotherapy. As a result, the survival benefit imparted by chemotherapy is primarily due to improvements in local control. 6, 7 In view of these findings we performed an observational study to observe the effectiveness of two drug chemotherapy regimen administered as induction treatment in patients with locally advanced unresectable head and neck cancer. The primary objective of this study is to compare progression free survival rate between study and group B. Secondary end points included assessment of overall survival, toxicities and organ preservation rate.
METHODS
This was a prospective study was conducted in the department of radiotherapy and oncology, Pravara rural hospital, Loni during period from August 2011 to July 2013. Total 102 Patients of locally advanced head and neck squamous cell carcinoma treated by faculty in the department of radiotherapy and oncology were included for the study. A written and informed consent was taken. Then patients were given induction chemotherapy and chemoradiotherapy as per the decision taken by faculty which was best for patient. Two cycles of chemotherapy were infused at an interval of 21days.
Inclusion criteria
Before infusion of chemotherapy complete blood count, RFT and LFT were done and should be within normal limit to start next cycle. Group B: Only chemoradiotherapy with Inj. cisplatin 30 mg/m2 weekly for 6-7 cycles was given.
Both groups have been treated with radiotherapy in a dose of 200 cGy per day for five day in a week up to 6600 to 7000 cGy.
Radiotherapy field include primary as well as lymphatic drainage area. Two parallel opposite portal was planned. After 4600 cGy spine was spared.
At the end of study following parameters were assessed:
1. Effectiveness: It was observed in terms of A. Response: After completion of definitive treatment in both group A and B.
B. Progression free survival: It was defined as the time from date of inclusion in either groups to disease progression or death from any cause without progression which ever occurred first.
2. Safety assessment: It was observed in terms of toxicities.
The patient toxicities evaluated daily during treatment and subsequent follow up and toxicities were graded according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). The response was evaluated after completion of the chemotherapy and radiotherapy.
Response evaluation is done by using RECIST 1.1 criteria.
RESULTS
From August 2011 to July 2013, total 102 patients were recruited. Out of these, group A included 48 patients and Group B had 54 patients respectively. All these patients have completed one and half year of follow up after completing definitive treatment. Response evaluation was done after six to eight weeks of completion of chemoradiotherapy in both arms. The baseline characteristics of our patient population are listed in Figure 2 . Median age of population was 55 years ranging from 22 -75 years.
Patient characteristics
48 patients received two drug regimen for two cycle followed by chemoradiotherapy and 54 patients received only chemoradiotherapy. 
Progression free survival
By applying Z test of proportion there is a significant difference between proportion of median progression free survival (PFS) between group A and group B. The median PFS in group A is significantly higher i.e. 11.5 months as compared to Group B i.e. 9 months.
Toxicity
The main toxicities NACT were vomiting (5%), neutropenia (5%), and diarrhea (4%).Grade III and Grade IV toxicities like mucositis, skin reactions and Bone marrow toxicity were common in group A. Even though the toxicities were high in group A as compared to group B, but they were tolerable and acceptable. 
Side effect of chemotherapy

DISCUSSION
This study provide follow-up of patients of locally advanced head and neck squamous cell carcinoma (HNSCC) treated with an neoadjuvant chemotherapy (NACT) with paclitaxel / cisplatin based regimen followed by concomitant cisplatin / radiation compared with only concomitant cisplatin / radiation. The indications for NACT are not well defined in clinical practice. NACT is used keeping in mind that it could help in control of micro metastasis and might downstage the tumour and hence making lesions operable. 8, 9 Only two positive phase III trials of induction chemotherapy have been published to date: the Gruppo di Studio sui Tumori della Testa e del Collo, which showed a survival benefit for patients who were considered ineligible for resection and the Groupe d'Etude des Tumeurs de la Teˆte et du Cou, which was limited to oropharynx cancer. Thus, the benefit of induction chemotherapy in clinical practice compared with the present standard CT/RT is unclear.
Our goal was to identify regimen that optimizes local and distant control for organ preservation and cure in patients with HNSCC. For this purpose we used paclitaxel and cisplatin as induction chemotherapy regimen. Our centre is a rural setup with economically poor patients who can not afford docetaxel and infusional 5FU based regimen with G-CSF support. So we modified our regimen to two drugs. Responses were radiologically evaluated 6-8 weeks after the end of treatment, consistently with the usual timing in clinical practice. However, no data on the best method and optimal timing for evaluating responses in SCCHN have been published to date.
In our study, complete response was achieved in 60.42% patients in group A and 38.88% patients in group B. Partial Response was seen in 22.92 % patients in group A and 55.56% patients in group B. Progressive disease was observed 16.66% and 05.56% patients in study and group B respectively. These results are quite similar with a study by Paccagella et.al. 10 a randomized phase 2 Italian study. Two groups were compared: TPF followed by chemoradiotherapy versus chemo radiotherapy alone.
During chemoradiotherapy, PF was used as the chemotherapy backbone in both groups. The primary endpoint was complete radiographic response. The study showed the sequential chemoradiotherapy group to be better than the concurrent group, with higher complete response rates: 21.2% for concurrent versus 50% for sequential. 15 These findings led to the Italian phase 3 study comparing the two treatments. This study has completed accrual and is waiting for sufficient follow-up before reporting. After a median follow-up of 42 months, 32 patients (62.7%) in arm A and 26 patients (52.0%) in arm B progressed or died; median PFS was 19.7 and 30.4 months, respectively. But in our study with median follow up of 13 months, the median progression free survival in group A was found to be significantly higher i.e. 11.5 months as compared to group B i.e. 9 months. Toxicities were acceptable with NACT (Group A) in our study with grade 3 and 4 neutropenia and thrombocytopenia in 3 and 2 % and vomiting in 3 and 2% respectively. The most relevant nonhematologic toxic effects (mucositis, skin toxicity, and diarrhea) were not much higher with group A as compared to group B. It also highlights that two drug combination of taxane with platinum needs to be investigated further to replace three drug combination.
CONCLUSION
In conclusion the results of our study indicate that induction chemotherapy with paclitaxel and cisplatin followed by concurrent chemoradiotherapy is superior to chemoradiotherapy in terms of radiological complete response and progression free survival. But in clinical practice the question of whether the addition of induction chemotherapy to concurrent chemoradiotherapy will improve survival over concurrent chemoradiotherapy alone remains unfortunately unanswered and it might be answered soon with more randomized phase III trials comparing both modalities. Both treatment modalities are effective in the treatment of head and neck cancer. A cost-benefit and quality-of-life analysis might prove beneficial in addressing the true value of induction chemotherapy. But the treating oncologist will have to decide about how to best treat patient, based on available evidence.
